These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 38866104)

  • 1. Real-World Data on Tezepelumab in Patients With Severe Asthma in Germany.
    Biener L; Mümmler C; Hinze CA; Suhling H; Korn S; Fisser C; Biener A; Pizarro C; Lenoir A; Hackl C; Skowasch D; Milger K
    J Allergy Clin Immunol Pract; 2024 Sep; 12(9):2399-2407.e5. PubMed ID: 38866104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tezepelumab for Severe Asthma: One Drug Targeting Multiple Disease Pathways and Patient Types.
    Panettieri R; Lugogo N; Corren J; Ambrose CS
    J Asthma Allergy; 2024; 17():219-236. PubMed ID: 38524099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option?
    Menzies-Gow A; Wechsler ME; Brightling CE
    Respir Res; 2020 Oct; 21(1):268. PubMed ID: 33059715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early response to Tezepelumab in type-2 severe asthma patients non-responders to other biological treatments: a real-life study.
    Jiménez-Gómez M; Díaz-Campos RM; Gimeno-Díaz-De-Atauri Á; Fernández-Rodríguez C; Fernández-Crespo J; García-Moguel I
    J Asthma; 2024 Oct; 61(10):1347-1350. PubMed ID: 38686823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tezepelumab in patients with allergic and eosinophilic asthma.
    Caminati M; Buhl R; Corren J; Hanania NA; Kim H; Korn S; Lommatzsch M; Martin N; Matucci A; Nasser SM; Pavord ID; Domingo C
    Allergy; 2024 May; 79(5):1134-1145. PubMed ID: 38146651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SOURCE: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma.
    Wechsler ME; Colice G; Griffiths JM; Almqvist G; Skärby T; Piechowiak T; Kaur P; Bowen K; Hellqvist Å; Mo M; Garcia Gil E
    Respir Res; 2020 Oct; 21(1):264. PubMed ID: 33050928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline type 2 biomarker levels and response to tezepelumab in severe asthma.
    Corren J; Pham TH; Garcia Gil E; Sałapa K; Ren P; Parnes JR; Colice G; Griffiths JM
    Allergy; 2022 Jun; 77(6):1786-1796. PubMed ID: 34913186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of tezepelumab in patients with evidence of severe allergic asthma: Results from the phase 3 NAVIGATOR study.
    Corren J; Ambrose CS; Griffiths JM; Hellqvist Å; Lindsley AW; Llanos JP; Colice G; Menzies-Gow A
    Clin Exp Allergy; 2023 Apr; 53(4):417-428. PubMed ID: 36507576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma.
    Menzies-Gow A; Colice G; Griffiths JM; Almqvist G; Ponnarambil S; Kaur P; Ruberto G; Bowen K; Hellqvist Å; Mo M; Garcia Gil E
    Respir Res; 2020 Oct; 21(1):266. PubMed ID: 33050934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study.
    Wechsler ME; Menzies-Gow A; Brightling CE; Kuna P; Korn S; Welte T; Griffiths JM; Sałapa K; Hellqvist Å; Almqvist G; Lal H; Kaur P; Skärby T; Colice G;
    Lancet Respir Med; 2022 Jul; 10(7):650-660. PubMed ID: 35364018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial.
    Diver S; Khalfaoui L; Emson C; Wenzel SE; Menzies-Gow A; Wechsler ME; Johnston J; Molfino N; Parnes JR; Megally A; Colice G; Brightling CE;
    Lancet Respir Med; 2021 Nov; 9(11):1299-1312. PubMed ID: 34256031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Biologics in Patients with Allergic Severe Asthma, Overall and by Blood Eosinophil Count: A Literature Review.
    Bernstein JA; Llanos JP; Hunter G; Martin N; Ambrose CS
    Adv Ther; 2023 Nov; 40(11):4721-4740. PubMed ID: 37698716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Potential Positioning of Tezepelumab in the Treatment of Severe Asthma.
    Plaza V; Cañete C; Domingo C; Martínez Rivera C; Muñoz X
    Open Respir Arch; 2023; 5(2):100231. PubMed ID: 37496871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CASCADE: a phase 2, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the effect of tezepelumab on airway inflammation in patients with uncontrolled asthma.
    Emson C; Diver S; Chachi L; Megally A; Small C; Downie J; Parnes JR; Bowen K; Colice G; Brightling CE
    Respir Res; 2020 Oct; 21(1):265. PubMed ID: 33050900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical Trials.
    Corren J; Menzies-Gow A; Chupp G; Israel E; Korn S; Cook B; Ambrose CS; Hellqvist Å; Roseti SL; Molfino NA; Llanos JP; Martin N; Bowen K; Griffiths JM; Parnes JR; Colice G
    Am J Respir Crit Care Med; 2023 Jul; 208(1):13-24. PubMed ID: 37015033
    [No Abstract]   [Full Text] [Related]  

  • 16. Real-life experience after 3 months with tezepelumab before marketing approval.
    Violán VV; Cano BG; Casero MÁR; González-Mancebo E; Vicente EM; Trujillo MJT; Gandolfo-Cano M
    Allergol Immunopathol (Madr); 2024; 52(2):80-82. PubMed ID: 38459894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tezepelumab Reduces Exacerbations Across All Seasons in Patients with Severe, Uncontrolled Asthma: A Post Hoc Analysis of the PATHWAY Phase 2b Study.
    Corren J; Karpefors M; Hellqvist Å; Parnes JR; Colice G
    J Asthma Allergy; 2021; 14():1-11. PubMed ID: 33469316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tezepelumab in the Treatment of Uncontrolled Severe Asthma.
    Feist J; Lipari M; Kale-Pradhan P
    Ann Pharmacother; 2023 Jan; 57(1):62-70. PubMed ID: 35535458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Positioning of Tezepelumab in Severe Asthma.
    Miralles-López JC; Antolín-Amérigo D; García-Moguel I; Domínguez-Ortega J; Delgado-Romero J; Quirce S
    J Investig Allergol Clin Immunol; 2024 Feb; 34(1):1-11. PubMed ID: 37812191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tezepelumab compared with other biologics for the treatment of severe asthma: a systematic review and indirect treatment comparison.
    Menzies-Gow A; Steenkamp J; Singh S; Erhardt W; Rowell J; Rane P; Martin N; Ackert JL; Quinton A
    J Med Econ; 2022; 25(1):679-690. PubMed ID: 35570578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.